4th Quarter - Report

RETIRESAFE for RETIRESAFE

Firm
Client
Income
—
Expenses
$6,742
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Joined the Voices for Non-Opioid Choices in support of payment policies that promote the choice and access to non-opioid pain medication, especially in the post surgical setting.

LobbyistCovered position, as disclosed
THAIR PHILLIPS —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Health Issues HCR

Support the quick implementation of the 21st Century Cures Act, specifically the provisions in the Act designed to speed up the Advisory Committee on Immunization Practices (ACIP) process through an established timeline so that much-needed new vaccines can be approved for coverage and use. Joined with numerous patient advocate organizations to urge Congress to maintain a strong and secure patent system that recognizes the rights of legitimate patent owners and addresses the new forms of abuses that have emerged in both the courts and at the U.S. Patent & Trademark Office (PTO), especially in consideration of the critical nature of strong patent protection in the development of new therapies and treatments that could benefit millions of patients suffering with substantial unmet medical needs. With National Health Council, urged CMS to include accurate drug-specific out-of-pocket (OOP) costs in the proposed OOP cost estimator under development for the federally-facilitated marketplaces. RetireSafe encouraged Members of Congress to hold a formal hearing to review FDA policy and guidance regarding the safe usage of biosimilar drugs. And, with other patient groups, advocated Risk Evaluation and Mitigation Strategies (REMS) and other rigorous safeguards to ensure the safe use of biosimilar drugs, especially for any federally mandated use. We also support the proposal that patient cost-sharing for most tiers and metal levels utilize reasonable cost-sharing, and oppose the use of coinsurance for the Specialty Drug Tier. We also repeated previous recommendations, and some new ones that would better protect enrollees access to needed prescription drugs, in addition to recommendations that would better ensure critical continuity of care. RetireSafe continues to join with other patient groups to urge the Food and Drug Administration (FDA) to require distinct, unique naming for any and all biosimilar drugs approved for use in the United States. We support the FDAs leadership in creating a system of distinguishable names for all biologic medicines, including biosimilars and interchangeable products. This system recognizes the fact that biosimilars are not exact copies of their reference products, enhances patient safety and promotes pharmacovigilance. RetireSafe supports HR 1920 which will correct the reduced payments to community oncologists. Signed onto a letter to President Trump with other organizations highlighting and promoting the value of vaccines. As a member of the Partnership for Safe Medicines, we supported a letter to Senators reminding them of the safety aspects involved with drug importation. As part of Alliance for Safe Biologics we encouraged the release of final guidance that supported the safe introductions of biosimilars.

LobbyistCovered position, as disclosed
THAIR PHILLIPS —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1920 (115th)

Medicare/Medicaid MMM

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, Worked with the MAPRx coalition and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program. Submitted comments on the CMS proposed changes to Medicare Part B. Submitted a letter to CMS concerning the coverage gap "cliff" that is facing older Americans. Continued our support of S. 2769, the Opioid Addiction Plan Act. Released a statement on the need to preserve the 6 protected classes of Medicare Part D drugs.

LobbyistCovered position, as disclosed
THAIR PHILLIPS —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S. 2769 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.